374559-48-5
374559-48-5 結(jié)構(gòu)式
基本信息
NA+,K+-ATPASE抑制劑(ISTAROXIME HYDROCHLORIDE)
PST-2774
PST2744 (hydrochloride)
PST-2744 (hydrochloride)
PST 2744 (hydrochloride)
IstaroxiMe (hydrochloride)
Istaroxime hydrochloride, >=98%
Istaroxime hydrochloride(PST2744)
(5alpha)-Androstane-3,6,17-trione 3-[O-(2-aminoethyl)oxime] monohydrochloride
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/12/22 | HY-15718A | ISTAROXIME 鹽酸鹽 Istaroxime hydrochloride | 374559-48-5 | 2mg | 950元 |
| 2025/12/22 | HY-15718A | ISTAROXIME 鹽酸鹽 Istaroxime hydrochloride | 374559-48-5 | 5mg | 1800元 |
| 2025/12/22 | HY-15718A | ISTAROXIME 鹽酸鹽 Istaroxime hydrochloride | 374559-48-5 | 10mM * 1mLin DMSO | 1980元 |
常見問題列表
IC50: 0.11 μM (Na + ,K + -ATPase)
Istaroxime hydrochloride acting as a positive inotropic compound through the inhibition of the Na + ,K + -ATPase. Istaroxime (PST2744) inhibits the Na + /K + -ATPase activity from dog kidney with an IC 50 value of 0.43 ± 0.15 μM. Inhibition of Na + /K + -ATPase activity in preparations from guinea pig kidney yielded potencies of 8.5 μM for PST2744.
Istaroxime (PST2744) induces a progressive increase in +dP/dt max throughout the infusion that reaches 80% (ED 80 ) at the cumulative dose of 1.89±0.37 mg/kg and a peak of 140±3.5% at the dose (ED max ) of 4.88±0.6 mg/kg.